Buy Medications
From the Best Modafinil & Provigil Store of
as per Customer Reviews
  • 100% MoneyBack Guarantee
  • Satisfaction guaranteed
  • Ultrafast Delivery
  • Affordable Canadian Pharmacy Online

Provigil And Acetaminophen

Provigil And Antibiotics - Provigil Use In The Elderly

Posted by Maurr on 2023-01-08

Major Concurrent administration of modafinil with ritonavir may result in elevated plasma concentrations of modafinil and decreased concentrations source ritonavir. Because the resultant effect of coadministration of a CYP3A4 inducer modafinil and inhibitor ritonavir on the plasma concentrations of these drugs is not defined, caution and close monitoring are advised if these drugs are administered together.

Deflazacort: Major Avoid concomitant use of deflazacort and modafinil.

Modafinil (Provigil)

Concurrent use may significantly decrease concentrations of desDFZ, the active metabolite of deflazacort, resulting link loss of efficacy. Desogestrel; Ethinyl Estradiol: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products.

Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Dexamethasone: Minor Drugs that exhibit significant induction of the hepatic microsomal CYP3A4 isoenzyme, such as dexamethasone, may potentially increase the metabolism of modafinil. Decreased serum levels of modafinil could potentially result in decreased efficacy of modafinil. Dextroamphetamine: Moderate The use of modafinil with other psychostimulants, including amphetamines e.

Diazepam: Moderate Modafinil has demonstrated an inhibition of the CYP2C19 hepatic microsomal isoenzyme Provigil And Acetaminophen pharmacologically relevant concentrations. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, may have prolonged elimination upon co-administration of modafinil.

Diclofenac: Moderate If possible, avoid concurrent use of diclofenac with inhibitors of CYP2C9, such as modafinil; if coadministration is required, do not exceed a total daily diclofenac dose of mg. Diclofenac; Misoprostol: Moderate If possible, avoid concurrent use of diclofenac with inhibitors of CYP2C9, such Provigil And Acetaminophen modafinil; if coadministration is required, do not exceed a total daily diclofenac dose of mg.

Dienogest; Estradiol valerate: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Dihydrocodeine; Guaifenesin; Pseudoephedrine: Moderate Concomitant use of dihydrocodeine with modafinil can decrease dihydrocodeine levels, resulting in less metabolism by CYP2D6 Provigil And Acetaminophen decreased dihydromorphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.

Diphenhydramine; Hydrocodone; Phenylephrine: Moderate Concomitant use of hydrocodone with modafinil can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. Dolutegravir: Moderate Dolutegravir plasma concentrations may be reduced when administered concurrently with modafinil; thereby increasing the risk for HIV treatment failures or the development of viral-resistance. Dolutegravir; Lamivudine: Moderate Dolutegravir plasma concentrations may be reduced when administered concurrently with modafinil; thereby increasing the risk for HIV treatment failures or the development of viral-resistance.

Dolutegravir; Rilpivirine: Moderate Close clinical monitoring is advised when administering modafinil with rilpivirine due to the potential for rilpivirine treatment failure. Moderate Dolutegravir plasma concentrations may be reduced when administered concurrently with modafinil; thereby increasing the risk for HIV treatment failures or the development of viral-resistance.

Donepezil: Minor The elimination of donepezil may be increased by concurrent administration of certain in vitro inducers of the hepatic isoenzymes CYP2D6 and CYP3A4 including modafinil. Doravirine: Moderate Concurrent administration of doravirine and modafinil may result in decreased doravirine exposure, resulting in potential loss of virologic control. Doravirine; Lamivudine; Tenofovir disoproxil fumarate: Moderate Concurrent administration of doravirine and modafinil may result in decreased doravirine exposure, resulting in potential loss of virologic control.

Doxercalciferol: Moderate Cytochrome P enzyme inhibitors, such as modafinil, may inhibit the hydroxylation of doxercalciferol, thereby decreasing the formation of the active metabolite and thus, decreasing efficacy. Inducers of CYP3A4 may decrease the concentration of doxorubicin and compromise the efficacy of chemotherapy. Avoid coadministration of modafinil and doxorubicin if possible.

If not possible, monitor doxorubicin closely for efficacy. Dronabinol: Moderate Use caution if coadministration of dronabinol with modafinil is necessary, and monitor for changes in the efficacy or adverse effect profile of dronabinol e. Concomitant use may result in altered plasma concentrations of dronabinol.

Drospirenone: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Drospirenone; Estetrol: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products. Drospirenone; Estradiol: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products. Drospirenone; Ethinyl Estradiol: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products.

Drospirenone; Ethinyl Estradiol; Levomefolate: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products.

Elagolix; Estradiol; Norethindrone acetate: Major Modafinil may Provigil And Acetaminophen failure of oral contraceptives or hormonal contraceptive-containing implants or devices due Provigil And Acetaminophen induction of CYP3A4 isoenzyme metabolism of the progestins in these products. Elbasvir; Grazoprevir: Major Concurrent administration of elbasvir with modafinil should be avoided if possible. Use of these drugs together is expected to decrease the plasma concentrations of elbasvir, and may result in decreased virologic response.

Major Concurrent administration of grazoprevir with modafinil should be avoided if possible. Provigil And Acetaminophen of these drugs together is expected to decrease the plasma concentrations of grazoprevir, and may result in decreased virologic response. Elvitegravir: Major Coadministration of elvitegravir with modafinil is not recommended as there is a potential for decreased elvitegravir concentrations. Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Alafenamide: Major Coadministration of cobicistat with modafinil is not recommended as there is a potential for elevated modafinil concentrations and decreased cobicistat concentrations.

Major Coadministration of elvitegravir with modafinil is not recommended as there is a potential for decreased elvitegravir concentrations. Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Disoproxil Fumarate: Major Coadministration of cobicistat with modafinil is not recommended as there is a potential for elevated modafinil concentrations and decreased cobicistat concentrations.

Empagliflozin; Linagliptin: Moderate Concomitant use of linagliptin with modafinil may result in decreased serum concentrations of linagliptin. Caution and close monitoring for decreased efficacy of linagliptin are advised if these drugs are used together.

Empagliflozin; Linagliptin; Metformin: Moderate Concomitant use of linagliptin with modafinil may result in decreased serum concentrations of linagliptin. Emtricitabine; Rilpivirine; Tenofovir alafenamide: Moderate Close clinical monitoring is advised when administering modafinil with rilpivirine due to the potential for rilpivirine treatment failure.

Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate: Moderate Close clinical monitoring is advised when administering modafinil with rilpivirine due to the potential for rilpivirine treatment failure.

Encorafenib: Major Avoid coadministration of encorafenib and modafinil due to decreased encorafenib exposure and potential loss of efficacy.

Coadministration with CYP3A4 inducers has not been studied with encorafenib; however, in clinical trials, steady-state encorafenib exposures were Provigil And Acetaminophen than encorafenib exposures after Provigil And Acetaminophen first dose, suggesting CYP3A4 auto-induction. Entrectinib: Major Avoid coadministration of entrectinib with modafinil due to decreased entrectinib exposure and risk of decreased efficacy.

Enzalutamide: Moderate Monitor for decreased efficacy of modafinil if coadministration with enzalutamide is necessary. The probability of effect of enzalutamide on modafinil exposure is low due to the please click for source of multiple pathways for modafinil metabolism, as well as the fact that a non-CYP-related pathway is the most rapid in metabolizing modafinil; however, plasma concentrations of modafinil may be impacted by strong CYP3A4 inducers.

Erdafitinib: Major If coadministration of erdafitinib and modafinil is necessary at the initiation of erdafitinib therapy, administer the dose of erdafitinib as recommended 8 mg once daily with potential to increase the dose to 9 mg on days 14 to 21 based on phosphate levels and tolerability.

If modafinil must be added to erdafitinib therapy after the initial dose increase period days 14 to 21increase the dose of erdafitinib up to 9 mg. If modafinil is discontinued, continue erdafitinib at the same dose in Provigil And Acetaminophen absence of drug-related toxicity.

Ergotamine; Caffeine: Moderate Caffeine is a Https://topmodafinilrxstore.com/7-is-provigil-a-psychiatric-drug-midaf.php and such actions are expected to be Provigil And Acetaminophen when coadministered with other CNS stimulants or psychostimulants.

Erlotinib: Major Avoid the coadministration of erlotinib with modafinil if possible due to the risk of decreased erlotinib efficacy. If concomitant use is unavoidable, increase the dose of erlotinib by 50 mg increments at 2-week intervals as tolerated, to a maximum of mg.

Coadministration may decrease plasma concentrations Provigil And Acetaminophen erlotinib. Erythromycin: Moderate Erythromycin can inhibit the hepatic metabolism of other drugs, such as modafinil, increasing their serum concentrations and potentially causing toxicity. Erythromycin; Sulfisoxazole: Moderate Erythromycin can inhibit the hepatic metabolism of other drugs, such as modafinil, increasing their serum concentrations and potentially causing toxicity. If these drugs are used together, monitor for reduced efficacy of escitalopram as well as escitalopram-associated adverse reactions.

Esketamine: Major Closely monitor blood pressure during concomitant use of esketamine and modafinil. Coadministration of psychostimulants, such as modafinil, with esketamine may increase blood pressure, including the possibility of hypertensive crisis. Estradiol Cypionate; Medroxyprogesterone: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Estradiol; Levonorgestrel: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products. Estradiol; Norethindrone: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Estradiol; Norgestimate: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Estradiol; Progesterone: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Ethanol: Major Advise patients to avoid alcohol-containing beverages while taking modafinil. There is no information on the effects of concurrent administration of ethanol or alcohol-containing medications with modafinil; the CNS depressant effect of alcohol may reduce the response to modafinil. Major Advise patients to avoid ethanol-containing beverages while taking modafinil. There is no information on the effects of concurrent administration of ethanol or ethanol-containing medications with modafinil; the CNS depressant effect of alcohol may reduce the response to modafinil.

Ethinyl Estradiol: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products. Ethinyl Estradiol; Levonorgestrel; Folic Acid; Levomefolate: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products.

Ethinyl Estradiol; Norelgestromin: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products.

Ethinyl Estradiol; Norethindrone Acetate: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products.

Ethinyl Estradiol; Norgestrel: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or Provigil And Acetaminophen due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products.

Ethynodiol Diacetate; Ethinyl Estradiol: Major Modafinil may cause failure of oral contraceptives Provigil And Acetaminophen hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products. Etonogestrel: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Etonogestrel; Ethinyl Estradiol: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products. Fedratinib: Major Avoid coadministration of fedratinib with modafinil as concurrent use may decrease fedratinib exposure which may result in decreased therapeutic response. The coadministration of fedratinib with a moderate CYP3A4 inducer has not been evaluated.

Fentanyl: Moderate Consider an increased dose of fentanyl and monitor for evidence of opioid withdrawal if concurrent use of modafinil is necessary. If modafinil is discontinued, consider reducing the fentanyl dosage and monitor for evidence of respiratory depression. Coadministration of a CYP3A4 inducer like modafinil with fentanyl, a CYP3A4 substrate, may decrease exposure to fentanyl resulting in decreased efficacy or onset of withdrawal symptoms in a patient who has developed physical Provigil And Acetaminophen to fentanyl.

Fentanyl plasma concentrations will increase once the inducer is stopped, which may increase or prolong the therapeutic https://topmodafinilrxstore.com/7-buy-provigil-cheap-mod.php adverse effects, including serious respiratory depression. Flibanserin: Major The concomitant use of flibanserin with CYP3A4 inducers significantly decreases flibanserin exposure compared to the use of flibanserin alone.

Therefore, concurrent use of flibanserin and CYP3A4 inducers, such as modafinil or armodafinil, is not recommended. In addition, modafinil and armodafinil are inhibitors of CYP2C19, a minor metabolic pathway of flibanserin. Azole antifungals, such as fluconazole, are significant inhibitors of this isoenzyme and may reduce the clearance of modafinil. Fluoxetine: Moderate Although no clinical data are available, fluoxetine may inhibit the clearance and potentiate the actions of modafinil.

Modafinil is metabolized by CYP3A4 isozyme, a pathway that fluoxetine is known to inhibit. Food: Moderate Food delays the rate, but not the extent, of modafinil absorption by approximately one hour. A delayed onset of action of a modafinil dose may result from this interaction, but this may not be clinically significant to the patient.

Patients may take modafinil with or without food. Moderate The incidence of marijuana associated adverse effects may change following coadministration with modafinil. Fosamprenavir: Major Caution is advised when administering modafinil with fosamprenavir, as concurrent use may reduce the plasma concentrations of fosamprenavir.

Modafinil is an inducer of Provigil And Acetaminophen hepatic isoenzyme CYP3A4. Amprenavir, the active metabolite of fosamprenavir, is a substrate of CYP3A4. Glasdegib: Major Avoid coadministration of glasdegib and modafinil due to the potential for decreased glasdegib exposure and risk of decreased efficacy. If concurrent use cannot be avoided, increase the glasdegib dosage i.

Resume the previous dose of glasdegib after modafinil has been discontinued for 7 days. Grapefruit juice: Moderate Grapefruit juice has been reported to decrease the metabolism of drugs that are metabolized via the CYP3A4 isoenzyme; grapefruit juice inhibits CYP3A4 in enterocytes. Because modafinil is significantly metabolized through CYP3A4, patients should be advised to not significantly alter their grapefruit juice ingestion. Green Tea: Major Some, but not all, green tea products contain caffeine.

Additive CNS stimulant effects are likely to occur when caffeine is coadministered with other CNS stimulants or psychostimulants. Caffeine should be avoided or used cautiously with modafinil. Guaifenesin; Hydrocodone: Moderate Concomitant use of hydrocodone with modafinil can decrease hydrocodone levels; Provigil And Acetaminophen may Provigil And Acetaminophen in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.

Guaifenesin; Hydrocodone; Pseudoephedrine: Moderate Concomitant use of hydrocodone with modafinil can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. Provigil And Acetaminophen Hydrocodone: Moderate Concomitant use of hydrocodone with modafinil can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.

Hydantoin concentrations may increase. Monitor carefully for signs of toxicity; phenytoin concentration monitoring may be helpful.

modafinil Drug Interactions - Epocrates Web

Hydrocodone: Moderate Concomitant use of hydrocodone with modafinil can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome Provigil And Acetaminophen patients who have developed physical dependence. Hydrocodone; Ibuprofen: Moderate Concomitant use of hydrocodone with modafinil can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.

Hydrocodone; Phenylephrine: Moderate Concomitant use of hydrocodone with modafinil can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. Hydrocodone; Potassium Guaiacolsulfonate: Moderate Concomitant use of hydrocodone with modafinil can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.

Hydrocodone; Potassium Guaiacolsulfonate; Pseudoephedrine: Moderate Concomitant use of hydrocodone with modafinil can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. Hydrocodone; Pseudoephedrine: Moderate Concomitant use of hydrocodone with modafinil can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.

Ibrutinib: Moderate Use ibrutinib and modafinil together with caution; decreased ibrutinib levels may occur resulting in reduced ibrutinib efficacy. Monitor patients for signs of decreased ibrutinib efficacy if these agents are used together. Simulations suggest that coadministration with a moderate CYP3A4 inducer may decrease ibrutinib exposure by 3-fold.

Ibuprofen; Oxycodone: Moderate Monitor for reduced efficacy of oxycodone and signs of opioid withdrawal if coadministration with modafinil is necessary; consider increasing the dose of oxycodone as needed. Ifosfamide: Moderate Closely monitor for increased Provigil And Acetaminophen toxicities e. Isavuconazonium: Major Coadministration of isavuconazonium with modafinil is not recommended as there is a potential for elevated modafinil concentrations Provigil And Acetaminophen decreased isavuconazonium concentrations.

Interactions between your drugs . A Major Drug Interaction exists between acetaminophen / hydrocodone and modafinil. View detailed information regarding this drug interaction.

Decreased isavuconazonium concentrations may lead to a reduction of antifungal efficacy and the potential for treatment failure. Isavuconazole, the active moiety of isavuconazonium, is a sensitive substrate and inhibitor of CYP3A4. It is known that many other CNS stimulants may induce severe cardiovascular and cerebrovascular responses if administered in combination with drugs with non-selective MAO inhibitor activity. Until more is known regarding the Provigil And Acetaminophen of modafinil, it is prudent avoid the use of modafinil in the presence of an MAO inhibitor.

Due to the prolonged duration of action of MAOIs, a period of at least 14 days between the last dose of the MAOI and the first dose of modafinil should elapse. Observation of the patient for increased effects from modafinil may be needed. Ivabradine: Major Avoid coadministration of ivabradine and modafinil. Coadministration may decrease the plasma concentrations of ivabradine resulting in the potential for treatment failure.

Caution should be utilized when CYP3A4 inducers are coadministered with ixabepilone, and alternative therapies Peovigil low enzyme induction potential should be considered. Azole antifungals are significant inhibitors of this isoenzyme and may reduce the clearance of modafinil.

Lansoprazole; Amoxicillin; Clarithromycin: Major Coadministration of modafinil and clarithromycin may decrease Provigil And Acetaminophen serum concentrations due to CYP3A4 enzyme induction.

Ptovigil Major Avoid coadministration of lefamulin with modafinil unless the benefits outweigh the risks as concurrent use may decrease lefamulin exposure and efficacy. Lemborexant: Major Avoid coadministration of lemborexant and modafinil as concurrent use may decrease lemborexant exposure which may reduce efficacy.

Letermovir: Major Concurrent administration of letermovir and modafinil is not recommended. Use of these drugs together may Provigil And Acetaminophen letermovir plasma concentrations, resulting in a potential loss of letermovir efficacy. Leuprolide; Norethindrone: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism Andd the progestins in these products.

Levonorgestrel: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Levonorgestrel; Ethinyl Estradiol: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products.

Levonorgestrel; Ethinyl Estradiol; Ferrous Bisglycinate: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products. Lidocaine: Moderate Concomitant use of systemic lidocaine and modafinil may decrease lidocaine plasma concentrations. Lidocaine; Epinephrine: Moderate Concomitant Provigli of systemic lidocaine and modafinil may decrease lidocaine plasma concentrations.

Lidocaine; Prilocaine: Moderate Concomitant use of systemic lidocaine and modafinil may decrease lidocaine plasma concentrations. Linagliptin: Moderate Concomitant use of linagliptin with modafinil may result in decreased serum concentrations of linagliptin.

Linagliptin; Metformin: Moderate Concomitant use of linagliptin with Acetaminophe may result in decreased serum concentrations of linagliptin. Linezolid: Moderate Linezolid is an antibiotic which is a reversible, non-selective inhibitor of MAO. Administration of modafinil to patients receiving linezolid may invoke a hypertensive reaction.

Such drugs should be avoided during and for up to Provigil And Acetaminophen weeks following the discontinuation of linezolid. Lisdexamfetamine: Moderate The use of modafinil with other psychostimulants, including amphetamines e.

Lonafarnib: Major Avoid coadministration of lonafarnib and modafinil; concurrent use may increase the exposure of lonafarnib and the risk of adverse effects. The exposure of modafinil Provifil also be increased.

If coadministration is Ans, closely monitor patients for adverse reactions from both drugs. Loperamide: Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with modafinil. Loperamide; Simethicone: Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with modafinil.

Lopinavir; Ritonavir: Major Concurrent administration of modafinil with ritonavir may result Acetmainophen elevated plasma concentrations of modafinil and decreased concentrations of ritonavir.

Lorlatinib: Major Avoid concomitant use of lorlatinib and modafinil due to decreased plasma concentrations of lorlatinib, which may reduce its efficacy. If concomitant use is necessary, increase the dose of lorlatinib to mg PO once daily. Lumateperone: Major Avoid coadministration of lumateperone and modafinil as concurrent use may decrease lumateperone exposure which may reduce efficacy. Lurasidone: Moderate Because lurasidone is primarily metabolized by CYP3A4, decreased plasma Acetamlnophen of lurasidone may occur when the drug is co-administered with inducers of CYP3A4.

Concurrent use of lurasidone and CYP3A4 inducers, such as modafinil, may lead to a decrease Avetaminophen efficacy of lurasidone. If lurasidone is used with a moderate Acetamminophen inducer, it may be necessary to increase the lurasidone dose after chronic treatment 7 days or more. Macimorelin: Major Discontinue modafinil and allow a sufficient washout period to pass before administering macimorelin.

Use of these drugs together can significantly decrease macimorelin plasma concentrations, and may result in a false positive test for growth hormone deficiency. Maraviroc: Moderate Use caution if coadministration Acteaminophen maraviroc Proviigil modafinil is necessary, due to a possible decrease in maraviroc exposure.

Monitor for a decrease in Provigli efficacy with concomitant use. Medroxyprogesterone: Major Modafinil may cause failure of oral contraceptives or hormonal Provigil And Acetaminophen implants or devices due to induction of CYP3A4 isoenzyme Provlgil of the progestins in these products.

Meloxicam: Moderate Consider a meloxicam dose reduction and monitor for adverse reactions if coadministration with modafinil is necessary. Mestranol is metabolized to ethinyl estradiol. Female patients of child-bearing potential Probigil be advised to discuss contraceptive options with their health care provider to prevent unintended pregnancies.

Methamphetamine: Moderate The use of modafinil with other psychostimulants, including amphetamines e. Acettaminophen Derivatives: Major The use of modafinil with other psychostimulants, including methylphenidate or its derivatives, has not been extensively studied.

Single dose studies of methylphenidate combined with modafinil noted that the rate of Accetaminophen of modafinil was delayed up to one hour Provigill the presence of methylphenidate; no changes occurred in the metabolism and extent of absorption of either medication.

Mitotane: Minor Avoid the concomitant use of mitotane with modafinil; if coadministration cannot be avoided, monitor for decreased efficacy of modafinil.

Mitotane is a strong CYP3A4 inducer. A non-CYP related pathway is the most rapid in metabolizing modafinil, suggesting that there is a low probability of substantive effects on the overall pharmacokinetic profile of modafinil due to CYP inhibition by concomitant medications; however, due to the partial involvement of CYP3A in modafinil metabolism, there is a potential for Acetamimophen plasma concentrations with strong CYP3A inducers such as mitotane. Monoamine oxidase inhibitors: Major Modafinil has not been evaluated for drug interactions with monoamine oxidase inhibitors MAOIs.

Nanoparticle Albumin-Bound Paclitaxel: Moderate Monitor for decreased efficacy of nab-paclitaxel if coadministration with modafinil is necessary due to the risk of decreased plasma concentrations of paclitaxel. Nanoparticle Albumin-Bound Sirolimus: Moderate Monitor for loss of Provigil And Acetaminophen of sirolimus during coadministration of modafinil; a sirolimus dose Aectaminophen may be necessary.

Monitor sirolimus serum concentrations as appropriate. Modafinil concentrations may increase with concurrent nefazodone use. Because modafinil is itself an inducer of the Provigil And Acetaminophen isoenzyme, drug interactions due to CYP3A4 enzyme inhibition by other Provigil And Acetaminophen may be complex and difficult to predict.

Neratinib: Major Avoid concomitant use of modafinil with neratinib due to decreased efficacy of neratinib. Provigil And Acetaminophen Ritonavir: Major Concurrent administration of modafinil with ritonavir may result in elevated plasma concentrations of modafinil and decreased concentrations of ritonavir. Moderate Monitor for a diminished response to nirmatrelvir if concomitant use of modafinil is necessary. Concomitant use of nirmatrelvir Provigik modafinil may reduce the therapeutic effect of nirmatrelvir.

Nisoldipine: Major Avoid coadministration of nisoldipine with modafinil due to decreased plasma concentrations of nisoldipine. Alternative antihypertensive therapy should be considered. Coadministration with a strong CYP3A4 inducer lowered nisoldipine plasma concentrations to undetectable levels.

Norethindrone Acetate; Ethinyl Estradiol; Ferrous fumarate: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl Acetaminopehn in these products. Porvigil Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Norethindrone; Ethinyl Estradiol: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products.

Norethindrone; Ethinyl Estradiol; Ferrous fumarate: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 Acefaminophen metabolism of ethinyl estradiol in these products. Norgestimate; Ethinyl Estradiol: Major Modafinil may Acetaminopheb failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of ethinyl estradiol Ane these products.

Norgestrel: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing Anxiety Cause Does Provigil or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products. Olanzapine; Fluoxetine: Moderate Although no clinical data are available, fluoxetine may inhibit the clearance and potentiate the actions of modafinil.

Olaparib: Major Avoid coadministration of olaparib with modafinil due to the risk of decreasing the efficacy of olaparib. Ombitasvir; Paritaprevir; Ritonavir: Contraindicated Acetaminlphen administration of modafinil with dasabuvir; ombitasvir; paritaprevir; ritonavir or ombitasvir; paritaprevir; ritonavir is contraindicated. Omeprazole; Amoxicillin; Rifabutin: Moderate Drugs that exhibit significant induction of the hepatic microsomal CYP3A4 isoenzyme may potentially increase the metabolism of modafinil.

These medications include rifabutin. Plasma concentrations and efficacy Acetamibophen modafinil may be reduced if these drugs are administered concurrently. Oxycodone: Moderate Monitor for reduced efficacy of oxycodone and signs of opioid withdrawal if coadministration with modafinil is necessary; consider increasing the dose of oxycodone as needed. Coadministration of pazopanib and modafinil, a CYP3A4 substrate, may cause an increase in systemic concentrations of modafinil.

In addition, modafinil is an inducer of CYP3A4 and may cause a decrease in systemic concentrations of pazopanib. Use caution when administering these drugs concomitantly. Pemigatinib: Major Avoid coadministration of pemigatinib and modafinil due to the risk of decreased pemigatinib exposure which may reduce its efficacy.

Pemoline: Major The use of modafinil with other psychostimulants, including pemoline, has Acetaninophen been extensively studied. Perampanel: Major Start perampanel at a higher initial dose of 4 Acehaminophen once daily at bedtime when using concurrently with modafinil due to Aceraminophen potential reduction in perampanel plasma concentration.

If introduction or withdrawal of modafinil occurs during perampanel therapy, closely monitor patient response; a dosage adjustment may be necessary. Moderate inducers of CYP3A4 can reduce pimavanserin exposure, potentially decreasing the effectiveness of pimavanserin. Posaconazole: Moderate Posaconazole and modafinil should be coadministered with caution due to an increased potential for modafinil-related adverse events. Posaconazole is a potent inhibitor of CYP3A4, an isoenzyme responsible for the https://topmodafinilrxstore.com/1-provigil-gaba-fod.php of modafinil.

These drugs used in combination may result in elevated modafinil plasma concentrations, causing an increased risk for modafinil-related adverse events. Praziquantel: Acetamijophen In vitro and drug interactions studies suggest that the CYP3A4 Acrtaminophen is the major enzyme involved in praziquantel metabolism.

Therefore, use of praziquantel with modafinil, a CYP3A4 inducer, should be done with caution as concomitant use may produce therapeutically ineffective concentrations of praziquantel. Progesterone: Major Modafinil may cause failure of Provgil contraceptives or hormonal contraceptive-containing implants or devices due to induction of Provogil isoenzyme Prrovigil of the progestins in these products.

Progestins: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

In Provigil And Acetaminophen, dosage reductions may be required for drugs that are largely eliminated via CYP2C19 metabolism such as propranolol during coadministration with rPovigil. Relugolix; Estradiol; Norethindrone acetate: Major Modafinil may cause failure of Ane contraceptives or hormonal contraceptive-containing implants or devices due to induction of CYP3A4 isoenzyme metabolism of the progestins in these products.

Ribociclib: Moderate Monitor for an increase Provigil And Acetaminophen modafinil-related adverse reactions if coadministration with ribociclib is necessary.

Modafinil (Provigil) - Side Effects, Interactions, Uses, Dosage, Warnings | Everyday Health

Modafinil has multiple pathways for metabolism including non-CYP-related pathways; however, due to Provigil And Acetaminophen involvement of the CYP3A enzymes, concomitant use of strong CYP3A4 inhibitors such as ribociclib could increase plasma concentrations of modafinil.

Ribociclib; Letrozole: Moderate Monitor for an increase in modafinil-related adverse reactions if coadministration with ribociclib is necessary.

Rifabutin: Moderate Drugs that exhibit significant induction of the hepatic microsomal CYP3A4 isoenzyme may potentially increase the metabolism of modafinil. Rifampin: Major Rifampin exhibits significant induction of the hepatic microsomal CYP3A4 isoenzyme and Provigil And Acetaminophen potentially increase the metabolism of modafinil. Rifapentine: Moderate Monitor for decreased efficacy of modafinil if coadministration with rifapentine is necessary. The probability of effect of rifapentine on modafinil Provigil And Acetaminophen is low due to the existence of multiple pathways for modafinil metabolism, as well as the fact that a non-CYP-related pathway is the most rapid in metabolizing modafinil; however, plasma concentrations of modafinil may be impacted by strong CYP3A4 inducers.

Rilpivirine: Moderate Close clinical monitoring is advised when administering modafinil with rilpivirine due to the potential for rilpivirine treatment failure. Riluzole: Moderate Coadministration of riluzole with modafinil may result in decreased riluzole efficacy.

In vitro findings suggest decreased riluzole exposure is likely. Rimegepant: Major Avoid coadministration of rimegepant with modafinil; concurrent use may Provigil And Acetaminophen decrease rimegepant exposure which may result in loss of efficacy. Ritonavir: Major Concurrent administration of modafinil with ritonavir may result in elevated plasma concentrations of modafinil and decreased concentrations of ritonavir.

Rivaroxaban: Minor Coadministration of rivaroxaban and modafinil may result in decreased rivaroxaban exposure and may decrease the efficacy of rivaroxaban. If these drugs are administered concurrently, monitor the patient for signs of lack of efficacy of rivaroxaban. Roflumilast: Major Coadminister modafinil and roflumilast cautiously as this may Provigil And Acetaminophen to reduced systemic exposure to roflumilast. In pharmacokinetic study, administration of a single dose of roflumilast in patients receiving another CYP3A4 inducer, rifampin, resulted in decreased roflumilast Cmax and AUC, as well as increased Cmax and decreased AUC of the active metabolite roflumilast N-oxide.

Coadministration of a CYP3A4 inducer, like modafinil, may decrease systemic concentrations of romidepsin. Use caution when concomitant administration of these agents is necessary. When used with drugs that are CYP3A4 inducers such as modafinil, a dose adjustment is not necessary, but closely monitor patients and titrate the ruxolitinib dose based on safety and efficacy. Segesterone Acetate; Ethinyl Estradiol: Major Modafinil may cause failure of oral contraceptives or hormonal contraceptive-containing implants or devices due to Provigil And Acetaminophen of CYP3A4 isoenzyme metabolism of ethinyl estradiol in these products.

Selegiline: Moderate Use caution during concomitant use of selegiline and modafinil. Modafinil has not been evaluated for drug interactions with monoamine oxidase inhibitors MAOIs ; however, it is known that many other CNS stimulants may induce severe cardiovascular reactions, such as hypertensive crisis, if administered in combination with drugs with non-selective MAO inhibitor activity.

Selpercatinib: Major Avoid coadministration of selpercatinib and modafinil due to the risk of decreased selpercatinib exposure which may reduce its efficacy. Selumetinib: Major Avoid coadministration of selumetinib and modafinil due to the risk of decreased selumetinib exposure which may reduce its efficacy. Sertraline: Moderate Dose adjustments of sertraline, a substrate for CYP2C19, may be necessary when used concomitantly with modafinil. Elimination of sertraline may be prolonged by modafinil via inhibition of CYP2C19, with resultant higher systemic exposure.

Monitor for adverse effects, such as serotonin excess, and reduce the sertraline dosage if needed. Simeprevir: Major Avoid concurrent use of simeprevir and modafinil. Induction of CYP3A4 by modafinil may significantly reduce the plasma concentrations of simeprevir, resulting in treatment failure.

Read article patients for adverse effects of modafinil, such as CNS effects. Sirolimus: Moderate Monitor for loss of efficacy of sirolimus during coadministration of modafinil; a sirolimus dose adjustment may be necessary.

Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Taking these drugs together may significantly decrease voxilaprevir plasma concentrations, potentially resulting in loss of antiviral efficacy. Solriamfetol: Moderate Monitor blood pressure and heart rate during coadministration of solriamfetol, a norepinephrine and dopamine reuptake inhibitor, and modafinil, a CNS stimulant. Coadministration of solriamfetol with other drugs that increase blood pressure or heart rate has not been evaluated.

Sonidegib: Major Avoid the concomitant use of sonidegib and modafinil; sonidegib exposure may be significantly decreased and its efficacy reduced. Avoid the use of sorafenib with a strong CYP3A4 inducer. If a strong CYP3A4 inducer must be coadministered with sorafenib, consider a sorafenib dose increase. John's Wort, Hypericum perforatum: Major St.

John's wort, Hypericum Perforatum may reduce the neuronal uptake of monoamines and should be used cautiously with sympathomimetics. Sufentanil: Moderate Because the dose of the sufentanil sublingual tablets cannot be titrated, consider an alternate opiate if modafinil must be administered. Monitor for reduced efficacy of sufentanil injection and signs of opioid withdrawal if coadministration with modafinil is necessary; consider increasing the dose of sufentanil injection as needed.

If modafinil is discontinued, consider a dose reduction of sufentanil injection and frequently monitor for signs or respiratory depression and sedation. Concomitant use with CYP3A4 inducers can decrease sufentanil concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.

Tasimelteon: Moderate Caution is recommended during concurrent use of tasimelteon and modafinil or armodafinil. Because tasimelteon is metabolized via CYP3A4 and CYP1A2, inducers of these isoenzymes, such as modafinil and armodafinil, may reduce the efficacy of tasimelteon.

Tazemetostat: Major Avoid coadministration of tazemetostat with modafinil as concurrent use may decrease tazemetostat exposure, which may reduce its efficacy. Telaprevir: Moderate Close clinical monitoring is advised when administering modafinil with telaprevir due to an increased potential for modafinil-related adverse events and the potential for telaprevir treatment failure.

If modafinil dose adjustments are made, re-adjust the dose upon completion of telaprevir treatment. Although this interaction has not been studied, predictions about the interaction can be made based on the metabolic pathways of modafinil and telaprevir. Modafinil is a substrate and inducer of the hepatic isoenzyme CYP3A4; telaprevir is a substrate and an inhibitor of this isoenzyme. When used in combination, the plasma concentrations of modafinil may increase and the plasma concentrations of telaprevir may decrease.

Telithromycin: Major Concomitant administration of CYP3A4 inducers, such as modafinil, are expected to cause subtherapeutic concentrations of telithromycin and loss of efficacy. In addition, telithromycin is Provigil And Acetaminophen competitive substrate and Provigil And Acetaminophen of CYP3A4; coadministration of telithromycin with other drugs metabolized by CYP3A4, such as modafinil, may result in increased plasma concentrations and an increase of therapeutic or adverse effects.

Temsirolimus: Moderate Use caution if coadministration of temsirolimus with modafinil Provigil And Acetaminophen necessary, and monitor for decreased efficacy of temsirolimus. The manufacturer of temsirolimus recommends a dose increase if coadministered with a strong CYP3A4 inducer, but recommendations are not available for concomitant use of moderate CYP3A4 inducers. Terbinafine: Moderate Caution is advised when administering terbinafine with modafinil.

Although this interaction has not been studied by the manufacturer, and published literature suggests the potential for interactions to be low, taking these drugs Provigil And Acetaminophen may alter the systemic exposure of terbinafine. Predictions about the interaction can be made based on the metabolic pathways of both drugs.

Monitor patients for adverse reactions and breakthrough fungal infections if these drugs are coadministered. The drug may induce the metabolism of some narrow-therapeutic index medications. Patients on theophylline or aminophylline may need to be monitored for reduced methylxanthine efficacy when modafinil is added to therapy. Provigil And Acetaminophen some cases, monitoring of theophylline concentrations may be helpful.

When modafinil is discontinued, monitor the patient for potential increases Всё Appetite Suppression Provigil Or Nuvigil горе theophylline concentrations. In some cases, monitoring of theophylline concentrations may be helpful. Modafinil is an inducer of CYP3A4.

Coadministration may result in reduced plasma concentration and subsequent reduced effectiveness of tolvaptan therapy and should be avoided. If coadministration is unavoidable, an increase in the tolvaptan dose may be necessary and patients should be monitored for decreased effectiveness of tolvaptan. Tranylcypromine: Major Modafinil has not been evaluated Provigil And Acetaminophen drug interactions with monoamine oxidase inhibitors MAOIs. Triazolam: Moderate Modafinil has been reported to induce the metabolism of triazolam via induction of the hepatic microsomal CYP3A4 isoenzyme.

PDR Search

If a patient is receiving triazolam and modafinil is introduced, monitor the patient for decreased clinical response to the benzodiazepine. Conversely, if modafinil is discontinued in such a patient, the triazolam dosage may need to be adjusted downward after modafinil cessation. Tucatinib: Moderate Monitor for an increase in modafinil-related adverse reactions if coadministration with tucatinib is necessary.

Modafinil has multiple pathways for metabolism https://topmodafinilrxstore.com/6-provigil-generic-india-hapa.php non-CYP-related pathways; however, due to partial involvement of the CYP3A enzymes, concomitant use of strong CYP3A4 inhibitors such as tucatinib could increase plasma concentrations of modafinil.

Ubrogepant: Major Increase the initial and second dose of ubrogepant to mg if coadministered with modafinil as concurrent use may decrease ubrogepant exposure and reduce its efficacy.

Concomitant use may decrease the plasma concentration Provigil And Acetaminophen effectiveness of ulipristal. Vemurafenib: Major Concomitant use of vemurafenib and modafinil may result in decreased concentrations of both agents. Both are CYP3A4 substrates and inducers. Use caution and monitor patients for therapeutic effects. Venetoclax: Major Avoid the concomitant use of venetoclax and modafinil; venetoclax levels may be decreased and its efficacy reduced.

Consider alternative agents. Use of venetoclax with a moderate CYP3A4 inducer has not been evaluated. Agents that induce CYP3A4 may increase the metabolism of Provigil And Acetaminophen and decrease the efficacy of drug, including modafinil. Patients receiving these drugs Provigil And Acetaminophen with vincristine should be monitored for possible loss of vincristine efficacy. Vorapaxar: Moderate Use caution during concurrent use of vorapaxar and modafinil. Decreased serum concentrations of vorapaxar and thus decreased efficacy are possible when vorapaxar, a CYP3A4 substrate, is coadministered with modafinil, a CYP3A inducer.

Voriconazole is a significant inhibitor of this isoenzyme and may reduce the clearance of modafinil. Headache, nausea and vomiting, nervousness, anxiety, and insomnia may worsen due to increased serum concentrations of modafinil. Voxelotor: Major Avoid coadministration of voxelotor and modafinil Provigil And Acetaminophen concurrent use may decrease voxelotor exposure and lead to reduced efficacy.

If coadministration is unavoidable, increase voxelotor dosage to 2, mg PO once daily. Warfarin: Moderate Closely monitor the INR if coadministration of Provigil And Acetaminophen with modafinil is necessary as concurrent use may increase or decrease the exposure of warfarin leading to increased bleeding risk or reduced efficacy. Zanubrutinib: Major Avoid the concomitant use of zanubrutinib and modafinil. Coadministration may result in decreased zanubrutinib exposure and reduced efficacy.

Zolpidem: Moderate It is advisable to closely monitor for reductions in zolpidem efficacy during co-administration of moderate CYP3A4 inducers, such as modafinil. CYP3A4 is the primary isoenzyme responsible for zolpidem metabolism, and there is evidence of significant decreases in systemic exposure and pharmacodynamics effects of zolpidem during co-administration of rifampin, a potent CYP3A4 inducer.

Mechanism of Action: The exact mechanism of modafinil's action in reducing somnolence is not fully understood. The enantiomers of modafinil appear to have similar pharmacologic profiles. Modafinil-induced wakefulness can be attenuated by the alpha-1 adrenergic antagonist, prazosin, which led to the initial conclusion that modafinil stimulates the central alpha-1 adrenergic system. However, in vitro assay systems responsive to alpha-adrenergic stimulation have not shown that modafinil is a direct or indirect alpha-1 adrenergic agonist.

The primary sites of modafinil's CNS activity appear to be in the subregions of the Provigil Ilaci, the centrolateral nucleus of the thalamus, and the central nucleus of the amygdala. Limited animal studies demonstrate that modafinil may increase excitatory glutaminergic transmission in the thalamus and hippocampus.

In contrast to the amphetamines and other CNS stimulants, the effects of modafinil do not appear to be mediated by dopamine or sympathomimetic systems. In vitro and in vivo studies demonstrate that modafinil does not bind to most of the neurochemical receptors involved in sleep-wake cycles, including norepinephrine, serotonin, dopamine, GABA, adenosine, histamine, monoamine oxidase B, and benzodiazepines. Modafinil also does not alter hormones associated with sleep regulation i.

Modafinil is not approved for use by anyone younger than 17 years old. Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Modafinil can cause skin reactions that may be severe enough to need treatment in a hospital. Stop taking this medicine and get emergency medical help if you have:. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. This medicine may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Avoid other dangerous activities until you know how modafinil will affect your level of wakefulness.

Use Modafinil Provigil exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow all directions on your prescription label.

Do not take this medicine in larger or smaller amounts or for longer than recommended. Modafinil may be habit-forming. Never share modafinil with another person, especially someone with a history of drug abuse or addiction. Keep the medication in a place where others cannot get to it. Selling or giving away modafinil is against the law. Modafinil is usually taken each morning to prevent daytime sleepiness, or 1 hour before the start of a work shift to treat work-time sleep disorders.

Read all patient information, medication guides, and instruction sheets provided to you. Ask your doctor or pharmacist if you have any questions.

If you are taking modafinil to treat sleepiness caused by obstructive sleep apnea, you may also be treated with a continuous positive airway pressure CPAP machine. This machine is an air pump connected to a mask that gently blows pressurized air into your nose while you sleep. The pump does not breathe for you, but the gentle force of air helps keep your airway open to prevent obstruction.

Do not stop using your CPAP machine during sleep unless your doctor tells you to. The combination of treatment with CPAP and modafinil may be necessary to best treat your condition. Modafinil will not cure obstructive sleep apnea or treat its underlying causes.

Follow your doctor's instructions about all your other treatments for this disorder. Keep track of the amount of medicine used from each new bottle. Modafinil is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription.

Talk with your doctor about what to do if you miss a dose of modafinil. Avoid taking the medicine if you do not plan to be awake for several hours. Skip the missed dose if it is almost bedtime. Do not take extra medicine to make up the missed dose. Health Conditions A-Z.

Health Tools. Modafinil Provigil.

WebMD provides information about common drug or vitamin interactions for modafinil oral. Common Brand(s): Provigil. Generic Name(s): modafinil. Overview. modafinil. Interaction Characteristics: CYP3A4 substrate; CYP2C19 inhibitor, weak; CYP3A4 inducer, major; hypertensive effects. Contraindicated.

  • Provigil Askapatient
  • Does Provigil Have Caffeine In It
  • Provigil Surgery
  • Where Can I Buy Provigil In Uk